NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Switch to English

10816	Sociétés
234391	Mots-clés
163227	Articles
125380	Communiqués

Accueil
Sociétés
NanoViricides, Inc.

COMMUNIQUÉ DE PRESSE

publié le 23/12/2024 à 12:30, il y a 1 année 7 mois

NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape
NanoViricides, Inc. announces that its antiviral drug candidate NV-387 shows promise in combating potential bird flu pandemic. The drug mimics essential host-side features, making it hard for the virus to escape

NanoViricides NV-387 Antiviral Drug H5N1 Bird Flu Pandemic
BRÈVE

publiée le 15/11/2024 à 12:35, il y a 1 année 8 mois

NanoViricides Advances NV-387 to Phase II Trials for Multiple Viral Infections

NanoViricides NV-387 Financial Report Clinical Trials Antiviral Drug
BRÈVE

publiée le 15/11/2024 à 12:35, il y a 1 année 8 mois

NanoViricides fait passer le NV-387 aux essais de phase II pour le traitement de multiples infections virales

NanoViricides NV-387 Rapport Financier Essais Cliniques Médicament Antiviral
COMMUNIQUÉ DE PRESSE

publié le 15/11/2024 à 12:30, il y a 1 année 8 mois

NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
NanoViricides, Inc. files Quarterly Report on Form 10-Q with the SEC, highlights financial results and progress on NV-387 antiviral drug for various infections including MPox and RSV

NanoViricides NV-387 Quarterly Report SEC Filing Antiviral Drug
BRÈVE

publiée le 04/11/2024 à 06:05, il y a 1 année 9 mois

NanoViricides Presents at Spartan Capital Investors Conference 2024

NanoViricides NV-387 Antiviral Nanomedicines Spartan Capital Conference Dr. Anil R. Diwan
BRÈVE

publiée le 04/11/2024 à 06:05, il y a 1 année 9 mois

NanoViricides présente sa nouvelle technologie à la conférence Spartan Capital Investors 2024

NanoViricides NV-387 Nanomédicaments Antiviraux Conférence Sur La Capitale Spartiate Dr Anil R. Diwan
COMMUNIQUÉ DE PRESSE

publié le 04/11/2024 à 06:00, il y a 1 année 9 mois

NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am
NanoViricides, Inc. to present corporate update at Spartan Capital Investors Conference on NV-387 antiviral drug development with strong market potential

NV-387 NanoViricides Inc. Market Potential Antiviral Drug Spartan Capital Investors Conference
BRÈVE

publiée le 22/10/2024 à 12:35, il y a 1 année 9 mois

NanoViricides President to Present at PODD Conference

NanoViricides NV-387 Drug Delivery PODD Conference Antiviral Treatments
BRÈVE

publiée le 22/10/2024 à 12:35, il y a 1 année 9 mois

Le président de NanoViricides fera une présentation à la conférence PODD

NanoViricides NV-387 Administration De Médicaments Conférence PODD Traitements Antiviraux
COMMUNIQUÉ DE PRESSE

publié le 22/10/2024 à 12:30, il y a 1 année 9 mois

NanoViricides President Dr. Diwan to Present at the PODD Conference
NanoViricides announces President Dr. Anil R. Diwan to speak at PODD Conference about revolutionary antiviral nanomedicines. Conference focuses on drug delivery partnerships and trends

NanoViricides Drug Delivery Antiviral Nanomedicines PODD Conference Anil R. Diwan

Les Echos

Publié le 10/08/2026 à 17:45, il y a 1 minute

Weekly share buyback
Publié le 10/08/2026 à 17:45, il y a 1 minute

Déclaration hebdomadaire de rachat d'actions
Publié le 10/08/2026 à 11:53, il y a 5 heures 52 minutes

GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
Publié le 10/08/2026 à 11:53, il y a 5 heures 52 minutes

GUILLEMOT CORPORATION |Informations relatives au nombre total de droits de vote et d’actions 31/07/2026
Publié le 10/08/2026 à 11:36, il y a 6 heures 10 minutes

GUILLEMOT CORPORATION| Weekly report share buyback from August 3 to August 7 2026

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 10/08/2026 à 15:30, il y a 2 heures 16 minutes

Silver Spruce Resources, Inc. Announces New Chief Financial Officer
Publié le 10/08/2026 à 15:25, il y a 2 heures 21 minutes

Gemdale Gold Intersects 5.19m at 14.01 g/t Au within 110m at 1.18 g/t Au at the Pontio Gold Project, Finland
Publié le 10/08/2026 à 14:30, il y a 3 heures 16 minutes

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
Publié le 10/08/2026 à 13:30, il y a 4 heures 16 minutes

Sterling Expands High-Grade Copper Mineralization East at MEPS Intersecting 203 Metres at 0.51% CuEq: Includes 16.25 Metres at 2.31% CuEq and 9.50 Metres at 2.34% CuEq within 445 Metres at 0.40% CuEq
Publié le 10/08/2026 à 13:00, il y a 4 heures 46 minutes

Alaska Energy Metals Announces Drilling Program for the Mcbride Prospect, Angliers-Belleterre Project, Quebec, Canada

Voir tout ACCESSWIRE

EQS Group

Publié le 10/08/2026 à 17:38, il y a 8 minutes

PATRIZIA delivers strong earnings growth with EUR 42.7m EBITDA (+46.6% y-o-y) in H1 2026
Publié le 10/08/2026 à 17:11, il y a 35 minutes

CORRECTION FROM SOURCE: North Peak Commences 2026 Drilling Campaign at Prospect Mountain, Eureka, Nevada
Publié le 10/08/2026 à 16:12, il y a 1 heure 34 minutes

dK Calls on PANDION AG Bondholders to Join Forces
Publié le 10/08/2026 à 15:56, il y a 1 heure 50 minutes

Viromed Medical AG signs distribution partnerships for ViroCAP® in six additional markets
Publié le 10/08/2026 à 15:46, il y a 2 heures

Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc